ASCO GU 2025: Optimizing Treatment Selection and Clinical Decision-Making in Advanced RCC - Episode 9

RCC Treatment Evolution: Expert Perspectives on the Evolving Landscape and Advances From ASCO GU 2025

, , ,

Experts discuss how treatment sequencing in advanced renal cell carcinoma (RCC) may evolve with the emergence of novel combinations and highlight emerging data from ASCO GU 2025 likely to impact clinical practice.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Long-Term Outcomes in Advanced RCC: Analyzing 8 Years of CheckMate 214 Data
    EP. 2: Optimizing IO-TKI Selection: Patient-Specific Approaches for Optimal Outcomes
    EP. 3: Long-Term Data From CheckMate 9ER Investigating Nivolumab Plus Cabozantinib in Untreated Advanced RCC
    EP. 4: RCC Treatment Selection: Expert Perspectives on Long-Term Data and Insights on Treatment Selection
    EP. 5: Optimizing IO/TKI Success: Managing Adverse Effects and Personalizing Treatment
    EP. 6: Navigating RCC Progression: Optimizing Treatment Sequence After the First Line
    EP. 7: Post-Immunotherapy Options in RCC: Latest Trial Data and Expert Perspectives on Rechallenge Strategies
    EP. 8: Emerging Therapies in RCC: Shaping Future Treatment Sequences
    Now Viewing
    EP. 9: RCC Treatment Evolution: Expert Perspectives on the Evolving Landscape and Advances From ASCO GU 2025

    Video content above is prompted by the following:

    Looking ahead, how do you see treatment sequencing evolving with the emergence of novel combinations? What emerging data from ASCO GU 2025 are most likely to impact clinical practice?

    x